Supplemental Newborn Screening by MS/MS-Based Second-Tier Testing
MN Newborn Screening Program
July 2008
If we look at the conditions that are currently screened for in Minnesota and who tests for which condition, the Minnesota Department of Health screens for biotinidase deficiency, cystic fibrosis, congenital adrenal hyperplasia, congenital hypothyroidism, galactosemia, and hemoglobinopathies. Whereas at the Mayo Clinic, we screen for amino acidopathies, organoacidopathies, and fatty acid oxidation disorders using tandem mass spectrometry. What you also see is that at the Mayo Clinic, we perform the second tier tests for congenital adrenal hyperplasia and several of the tandem mass spectrometry tests.
MN Newborn Screening Program |
Jump to section:
- Introduction
- What is Newborn Screening?
- Evolution of Newborn Screening
- ACMG* Uniform Panel
- MS/MS Impact on Newborn Screening
- Newborn Screening Performance in the USA (MS/MS)
- Costs of False-Positive NBS Results
- Newborn Screening in Minnesota
- MN Newborn Screening Program
- Costs of False-Positive NBS Results
- What is Second-Tier Testing?
- Second-Tier Testing is Performed for the Following "Problem" Analytes
- Why Second-Tier Testing?
- Costs of False-Positive NBS Results
- Impact of Second-Tier Testing on Performance of Newborn Screening by MS/MS at Mayo Clinic
- Questions?
External
link
PDF
document
Excel
document
Word
document